News European safety experts review latest hepatitis C drugs European safety experts are reviewing the latest generation of hepatitis C drugs following cases of re-activation of hepatitis B in patients treated with the medicines, who had been infecte
Views & Analysis Hepatitis C: breaking down the stigma David Rowlands' latest online poll examines the impact of stigma on people diagnosed with hepatitis C virus (HCV).
Articles Raising the bar: can Gilead’s next challenge be even bigger ... How do you follow a genuine drug breakthrough, a cure for hepatitis C?
Articles NICE calls the shots on Harvoni – but NHS England eyeing pri... Harvoni and rival hep C drugs look set for approval in England – but NHS England may have the last word on controlling costs, finds Andrew McConaghie.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.